非霍奇金淋巴瘤临床疗效与预后评价的现状和进展  

Status and Progress of Clinical Efficacy and Prognostic Evaluation of Non-Hodgkin's Lymphoma

作　　者：杜美莲[1] 周永明[1] 张广社 

机构地区：[1]上海中医药大学附属岳阳中西医结合医院血液内科,上海200437

出　　处：《医学综述》2013年第22期4081-4084,共4页Medical Recapitulate

基　　金：上海市卫生局中医药科研基金(2010L040A)

摘　　要：为了更好地评价非霍奇金淋巴瘤(NHL)的临床疗效和预后,通过复习国内外相关文献,发现多种指标可以有效地运用于临床,包括传统评价国际预后指数、病理类型、临床分期、治疗方法、初治疗效、病灶稳定或病灶进展、最大肿瘤直径、结外受累部位数、乳酸脱氢酶等以及新近评价肿瘤标志物CA125、分子生物学指标、免疫及相关指标、正电子射出断层造影CT中2-氟-2-脱氧-D-葡萄糖最大标化摄取值等。该文就NHL病临床疗效与预后评价的相关指标予以综述。Through reviewing related literatures a variety of indicators are found in order to better evalu- ate the clinical efficacy and prognosis of non-Hodgkin＇s lymphoma,which can be effectively used in the clini- cal, including the traditional evaluation indicators such as IPI, pathological type, clinical staging, treatment site number, the effect of early treatment, lesion stability or lesions progress,the largest tumor diameter, extranodal involvement value, LDH, and recent evaluation indicators such as tumor marker CA125, molecular markers,immune and related indicators of PET/CT FDG maximum standardized uptake. Here is to make a review of the clinical efficacy and prognostic evaluation indicators of non-Hodgkin＇s lymphoma.

关 键 词：非霍奇金淋巴瘤 临床疗效 临床预后 评价 

分 类 号：R559[医药卫生—血液循环系统疾病]